Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine (DCS)
Schizophrenia, Bipolar Disorder
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring D-cycloserine, Glycine, Psychosis, Mutation, GABA
Eligibility Criteria
Inclusion Criteria:
- Carriers of a triplication in the glycine decarboxylase gene
Exclusion Criteria:
- Not carriers of a triplication in the glycine decarboxylase gene
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Open label DCS
DCS or placebo
Second open label DCS
Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule for 8 weeks.
Randomized to DCS or placebo. Participants underwent double-blind placebo-controlled exposures to DCS for 6 weeks or placebo for 6 weeks. One participant received exposure to DCS for 6 weeks and then received placebo dosing for 6 weeks. The other participant received exposure to placebo dosing for 6 weeks and then DCS for 6 weeks.
Both participants received second open label exposures to D-cycloserine (seromycin), 50 mg/d capsule for 24 weeks.